Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D3 and 1alpha-hydroxyvitamin D3 on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet
- 5 November 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 151 (1) , 76-85
Abstract
Summary: Frequent injections of the hormonal form of vitamin D3, 1,25 dihydroxyvitamin D3 (1,25D3) reportedly inhibits autoimmune type 1 diabetes (T1D) in non-obese diabetic (NOD) mice by correcting some of the abnormalities in antigen-presenting cells which contribute the development of pathogenic T cell responses. This route of administration greatly elevates the levels of these compounds in the bloodstream for hours after treatment, which requires mice to be fed diets formulated to contain much reduced levels of Ca to avoid the toxic effects of hypercalcaemia. In the current work, we demonstrate that feeding 1,25D3 or its synthetic precursor, 1alpha(OH) vitamin D3 (1alphaD3), as part of a T1D supportive chow diet containing normal levels of Ca, is an effective means of reducing the incidence of disease in NOD mice, but the doses required for protection elicited hypercalcaemia. However, T1D protection elicited by D3 analogue feeding appears, at least partially, to have an immunological basis, as splenic T cells from treated mice had a decreased capacity to adoptively transfer disease. Protection is associated with an increased proportion of T cells with CD4+ forkhead box P3+ regulatory phenotype within the islet infiltrate of treated animals. The 1alphaD3 precursor is converted rapidly to the active 1,25D3 isoform in vivo. However, feeding the 1alphaD3 analogue elicited stronger T1D protection than the 1,25D3 compound, but also induced more severe hypercalcaemia. In future, the dietary supplementation of novel low-calcaemic D3 analogues may enable their continuous delivery at levels that inhibit T1D development in susceptible humans consuming normal levels of Ca.Keywords
This publication has 46 references indexed in Scilit:
- Vitamin D and type 1 diabetes mellitus: state of the artTrends in Endocrinology & Metabolism, 2005
- Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune systemThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Potent Inhibition of Dendritic Cell Differentiation and Maturation by Vitamin D AnalogsBiochemical and Biophysical Research Communications, 2000
- Activity of various hydroxylated vitamin D3 analogs for improving phosphorus utilisation in chicks receiving diets adequate in vitamin D3British Poultry Science, 1998
- Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene.Journal of Clinical Investigation, 1998
- Targeted Expression of Major Histocompatibility Complex (MHC) Class II Molecules Demonstrates that Dendritic Cells Can Induce Negative but Not Positive Selection of Thymocytes In VivoJournal of Experimental Medicine, 1997
- Defective maturation and function of antigen-presenting cells in type 1 diabetesThe Lancet, 1995
- Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3Diabetologia, 1994
- Defective HLA class II expression in monocytes of type 1 diabetic patientsAPMIS, 1993
- The comparative toxicity of vitamin D metabolites in the weanling mouseToxicology and Applied Pharmacology, 1985